Current Report Filing (8-k)
January 18 2017 - 1:36PM
Edgar (US Regulatory)
UNITED
STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM
8-K
CURRENT
REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date
of report (Date of earliest event reported): January 18, 2017
Immunomedics,
Inc.
(Exact
Name of Registrant as Specified in its Charter)
Delaware
|
|
000-12104
|
|
61-1009366
|
(State
or Other Jurisdiction
of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer
Identification No.)
|
300
The American Road, Morris Plains, New Jersey
|
|
07950
|
(Address
of principal executive offices)
|
|
(Zip
Code)
|
(973)
605-8200
(Registrant’s telephone number, including area code)
Not
applicable
(Former Name or Former Address, if Changed Since Last Report)
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
|
|
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
|
|
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
|
Item
7.01. Regulation FD Disclosure.
On
January 18, 2017, Immunomedics, Inc. issued a press release titled “Immunomedics Highlights Expanded Pipeline Positioning
Company for Sustained Value Creation.” The full text of the press release is attached to this current report on Form 8-K
as Exhibit 99.1 and is incorporated by reference herein.
Item
9.01 Financial Statements and Exhibits.
(d)
Exhibits.
Exhibit
No.
|
|
Description
of Exhibit
|
99.1
|
|
Press
Release of Immunomedics, Inc., dated January 18, 2017, titled “Immunomedics Highlights Expanded Pipeline Positioning
Company for Sustained Value Creation.”
|
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
IMMUNOMEDICS, INC.
|
|
|
|
By:
|
/s/
Michael R. Garone
|
|
Name:
|
Michael
R. Garone
|
|
Title:
|
Vice
President, Finance and Chief Financial Officer
|
|
|
|
Date:
January 18, 2017
|
|
|
Exhibit
Index
Exhibit
No.
|
|
Description
of Exhibit
|
99.1
|
|
Press
Release of Immunomedics, Inc., dated January 18, 2017, titled “Immunomedics Highlights Expanded Pipeline Positioning
Company for Sustained Value Creation.”
|
4
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Aug 2024 to Sep 2024
Immunomedics (NASDAQ:IMMU)
Historical Stock Chart
From Sep 2023 to Sep 2024